Gilead’s Gritstone vaccine deal adds yet another shot on goal for HIV cure

The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships Gilead has signed in its search for an HIV cure.